Marie McNulty

Title: Marie McNulty: Innovator in Pharmaceutical Sciences

Introduction

Marie McNulty is a distinguished inventor based in Dublin, Ireland. She has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative treatments for inflammatory diseases. With a total of two patents to her name, McNulty's work is paving the way for advancements in medical therapies.

Latest Patents

Marie McNulty's latest patents include "IL-34 antisense agents and methods of using same." This patent discloses polynucleotides that are complementary to IL-34, including IL-34 antisense oligonucleotides and IL-34 nucleic acids. These innovations are aimed at treating inflammatory diseases, such as inflammatory bowel disease and fibrosis, which are associated with elevated activity or expression of IL-34. Additionally, her patent outlines pharmaceutical compositions containing these polynucleotides, which are useful for treating such diseases and for the manufacture of medicaments. Another notable patent is for the "Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof." This disclosure provides a process for preparing compounds that are capable of modulating the activity of receptors, such as PPARs receptors.

Career Highlights

Marie McNulty is currently associated with Nogra Pharma Limited, where she continues to innovate and contribute to the pharmaceutical industry. Her work is characterized by a commitment to developing effective treatments that address significant health challenges.

Collaborations

Some of her notable coworkers include Francesca Viti and Salvatore Demartis, who collaborate with her on various projects within the company.

Conclusion

Marie McNulty's contributions to pharmaceutical sciences through her innovative patents and collaborative efforts highlight her role as a key inventor in the field. Her work continues to inspire advancements in the treatment of inflammatory diseases.